Old Runner Guy wrote:
......by a team headed by Fu-Kuen Lin at U.S. biotechnology company Amgen.......
Good ol Fukuen Lin....guess that's who the Balco founder was trying to implicate when he yelled at the judge handing down the sentence....
Old Runner Guy wrote:
......by a team headed by Fu-Kuen Lin at U.S. biotechnology company Amgen.......
Good ol Fukuen Lin....guess that's who the Balco founder was trying to implicate when he yelled at the judge handing down the sentence....
alsoclueless wrote:
How much improvement would that average runner get out of it?
And all for some divisional awards?
So lame.
The short answer, in my opinion, is not much. EPO works by increasing the oxygen carrying capabilities of the blood. For elite athletes this can be a limiting factor or co-factor in performance although not the primary one.
For sub-elite athletes it is nowhere close to the the limiting factor for any event. For the longer distances mitochondrial density is the primary limiting factor, for mid distances anaerobic capacity also plays a huge part. But for none of them does serum O2 concentration come anywhere close to until a lot of other optimization have taken place.
Anyone with more knowledge than me have an opinion?
Fukein right it works, the drug co's that mfg EPO are doing very well. ANY MD in the country has this stuff sitting in a cabinet in his/her office and it moves quickly. It works. I know.
I spoke the truth.
Go back to wanking off and believe what you want.
Oh Fuk wrote:
Fukein right it works, the drug co's that mfg EPO are doing very well. ANY MD in the country has this stuff sitting in a cabinet in his/her office and it moves quickly. It works. I know.
EPO sales are $10 billion a year. It's also made in a generic version, EPOgen. Some Anemina patients have to take it for life. So, they are looking for cheap sources. This is why the off-shore drug stors that sell it cheaply online have a legit purpose.
It's a huge and important drug. A tiny amount of the volume of EPO produced each year is used as a PED.
noNameMcgee wrote:
There are a couple of masters runners out here in my town in California that I kind of wondered about with the regards to getting some "performance enhancment"
I am staying out of this and let karma do it's work.
Hey noNameMcgee, this thread would be way more fun if you would name names. At least give us a hint. What town is "my town?" What age group do these runners run in? Come'on, they cheated, they deserve to be called out.
[/quote]
Hey noNameMcgee, this thread would be way more fun if you would name names. At least give us a hint. What town is "my town?" What age group do these runners run in? Come'on, they cheated, they deserve to be called out.[/quote]
if it's PAUSATF, it's northern California: San Francisco Bay Area, Central Valley, Sacramento or SLO. could be missing some areas but this is the majority of the PA
Oh please. I heard from one of your best friends that you were going to pull this shit. He can't believe you actually went ahead and posted. He said he was going to talk to you about it, but thought, "Hey, if the guy wants to make an ass out of himself, then that's his right."
He says you're just pissed because your times have been slow and some old guy beat you in a race.
Old Runner Guy wrote:
EPO sales are $10 billion a year. It's also made in a generic version, EPOgen.
Epogen isn't generic, it's Amgen's trademark.
Mork wrote:
Epogen isn't generic, it's Amgen's trademark.
My bad, typing too fast
If your good EPO makes a difference. I never tried it. But I have tried Gookinaid..
Sub-cut admin a couple of times a week will remove the dangers and expense of iv infusions of EPO. Difficulty is then getting a prescription or finding a bent pharmacist to supply you...
"UK drugmaker Shire has initiated a new Phase IIIb clinical trial to evaluate two new dosing schedules for Dynepo its erythropoiesis-stimulating agent intended for the treatment of anaemia in patients with chronic kidney disease.
Patients with anaemia have reduced haemoglobin levels and the firm noted that Dynepo has previously been shown to be as effective as epoetin alfa in increasing and then maintaining haemoglobin levels in the target range (10-12g/dL) in patients with anaemia associated with CKD when initially given three times per week by the intravenous route. Shire added that it is also effective when given twice per week via the subcutaneous route.
The new open-label study will investigate the efficacy and safety profiles of different starting doses of the agent administered by subcutaneous injection, which are at a lower frequency (once-weekly and once every two weeks) than those currently approved for subcutaneous administration.
Dynepo is the first erythropoiesis-stimulating agent (ESA) to be produced by in a human cell line, via activation of the gene which codes for erythropoietin in human cells, rather than cloning and transferring these genes into animal cells, the method by which rival drug Epogen (epoetin alfa) from Amgen is produced.
Despite this difference, Shire is effectively blocked from launching the product in the USA after an appeals court in August ruled that it infringed two Amgen patents, but could be in a position to introduce it in Europe next year."
My best friend is your mom.
Nice
The advantage to that drug is that you need less injections, but it has a longer biological half life than Epogen. This makes it a lot easier to detect (assuming this is also made in CHO cells). .
where there's a will... wrote:
Sub-cut admin a couple of times a week will remove the dangers and expense of iv infusions of EPO. Difficulty is then getting a prescription or finding a bent pharmacist to supply you...
"UK drugmaker Shire has initiated a new Phase IIIb clinical trial to evaluate two new dosing schedules for Dynepo its erythropoiesis-stimulating agent intended for the treatment of anaemia in patients with chronic kidney disease.
Patients with anaemia have reduced haemoglobin levels and the firm noted that Dynepo has previously been shown to be as effective as epoetin alfa in increasing and then maintaining haemoglobin levels in the target range (10-12g/dL) in patients with anaemia associated with CKD when initially given three times per week by the intravenous route. Shire added that it is also effective when given twice per week via the subcutaneous route.
The new open-label study will investigate the efficacy and safety profiles of different starting doses of the agent administered by subcutaneous injection, which are at a lower frequency (once-weekly and once every two weeks) than those currently approved for subcutaneous administration.
Dynepo is the first erythropoiesis-stimulating agent (ESA) to be produced by in a human cell line, via activation of the gene which codes for erythropoietin in human cells, rather than cloning and transferring these genes into animal cells, the method by which rival drug Epogen (epoetin alfa) from Amgen is produced.
Despite this difference, Shire is effectively blocked from launching the product in the USA after an appeals court in August ruled that it infringed two Amgen patents, but could be in a position to introduce it in Europe next year."
[quote]Skinny weird Guy wrote:
The advantage to that drug is that you need less injections, but it has a longer biological half life than Epogen. This makes it a lot easier to detect (assuming this is also made in CHO cells). [quote]
From
http://en.wikipedia.org/wiki/Erythropoietin
If Dynepo becomes available as a pharmaceutical product in 2006 as expected, it may be a boon to doping athletes. It is to be manufactured in cultured human cells and should thus have an authentic pattern of human glycosylation, making it undetectable by the current test method.
Come on NoName.....Grow a pair and drop some names.....if you can't stand the heat.....get out of the fire......So far your just coming off like a whiner whose tired of getting beat by these guys.....
Opps, I didn't do all of my homework.
Old Runner Guy wrote:
[quote]Skinny weird Guy wrote:
The advantage to that drug is that you need less injections, but it has a longer biological half life than Epogen. This makes it a lot easier to detect (assuming this is also made in CHO cells). [quote]
From
http://en.wikipedia.org/wiki/ErythropoietinIf Dynepo becomes available as a pharmaceutical product in 2006 as expected, it may be a boon to doping athletes. It is to be manufactured in cultured human cells and should thus have an authentic pattern of human glycosylation, making it undetectable by the current test method.